| 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma MS Kaminski, M Tuck, J Estes, A Kolstad, CW Ross, K Zasadny, D Regan, ... New England Journal of Medicine 352 (5), 441-449, 2005 | 880 | 2005 |
| Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 … CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 2008 | 757 | 2008 |
| Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ... Journal of Clinical Oncology 26 (32), 5156-5164, 2008 | 528 | 2008 |
| TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy CW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 2017 | 362 | 2017 |
| Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem‐cell support … CH Geisler, A Kolstad, A Laurell, M Jerkeman, R Räty, NS Andersen, ... British journal of haematology 158 (3), 355-362, 2012 | 326 | 2012 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial NH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ... Nature medicine 28 (2), 325-332, 2022 | 274 | 2022 |
| 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ... British journal of haematology 175 (3), 410-418, 2016 | 220 | 2016 |
| The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line … CH Geisler, A Kolstad, A Laurell, R Räty, M Jerkeman, M Eriksson, ... Blood, The Journal of the American Society of Hematology 115 (8), 1530-1533, 2010 | 212 | 2010 |
| Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases A Hadzidimitriou, A Agathangelidis, N Darzentas, F Murray, ... Blood, The Journal of the American Society of Hematology 118 (11), 3088-3095, 2011 | 209 | 2011 |
| The Patient Experiences Questionnaire: development, validity and reliability KI Pettersen, M Veenstra, B Guldvog, A Kolstad International Journal for Quality in Health Care 16 (6), 453-463, 2004 | 205 | 2004 |
| High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells JH Myklebust, JM Irish, J Brody, DK Czerwinski, R Houot, HE Kohrt, ... Blood, The Journal of the American Society of Hematology 121 (8), 1367-1376, 2013 | 186 | 2013 |
| Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment OE Yri, D Torfoss, O Hungnes, A Tierens, K Waalen, T Nordøy, S Dudman, ... Blood, The Journal of the American Society of Hematology 118 (26), 6769-6771, 2011 | 186 | 2011 |
| Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion R Houot, MJ Goldstein, HE Kohrt, JH Myklebust, AA Alizadeh, JT Lin, ... Blood, The Journal of the American Society of Hematology 114 (16), 3431-3438, 2009 | 163 | 2009 |
| Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma NS Andersen, LB Pedersen, A Laurell, E Elonen, A Kolstad, AM Boesen, ... Journal of Clinical Oncology 27 (26), 4365-4370, 2009 | 159 | 2009 |
| SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic Lymphoma Group study L Nordström, S Sernbo, P Eden, K Grønbaek, A Kolstad, R Räty, ... British journal of haematology 166 (1), 98-108, 2014 | 151 | 2014 |
| Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial M Jerkeman, CW Eskelund, M Hutchings, R Räty, KF Wader, A Laurell, ... The Lancet Haematology 5 (3), e109-e116, 2018 | 139 | 2018 |
| Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway T Risberg, A Kolstad, Y Bremnes, H Holte, EA Wist, O Mella, O Klepp, ... European Journal of Cancer 40 (4), 529-535, 2004 | 136 | 2004 |
| KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study S Ferrero, D Rossi, A Rinaldi, A Bruscaggin, V Spina, CW Eskelund, ... Haematologica 105 (6), 1604, 2020 | 129 | 2020 |
| Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae T Nordøy, IS Aaberge, A Husebekk, HH Samdal, S Steinert, H Melby, ... Medical Oncology 19, 71-78, 2002 | 126 | 2002 |
| Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients … H Holte, S Leppä, M Björkholm, Ø Fluge, S Jyrkkiö, J Delabie, ... Annals of oncology 24 (5), 1385-1392, 2013 | 125 | 2013 |
